This is an active lawsuit, and none of the allegations against the defendant(s) have been proven. The contents of this page reflect the allegations in the lawsuits.
Drug manufacturers Sanofi and Regeneron are facing accusations that the injectable biologic medication Dupixent can cause cutaneous T-cell lymphoma (CTCL). Many patients have filed lawsuits alleging an increased risk of CTCL linked to Dupixent, and at least one family has reportedly filed a wrongful death lawsuit as well.
These lawsuits allege that Sanofi and Regeneron failed to warn patients and healthcare providers that Dupixent might cause this rare and aggressive form of skin cancer (CTCL is a form of non-Hodgkin lymphoma). In their lawsuits, patients and families are seeking compensation for their medical expenses, loss of earnings, and other financial and non-financial losses. Since Dupixent lawsuits are still in their early stages, the allegations against Sanofi and Dupixent have not yet been proven, and we are not aware of any patients or families that have received compensation for their losses.
“Dupixent lawsuits allege that the drug’s manufacturers failed to warn asthma patients and others about the prescription drug’s link to the rare but aggressive form of skin cancer, cutaneous T-cell lymphoma (CTCL). Patients who developed CTCL after using this injectable medication are encouraged to speak with an attorney about their legal rights.” – Dr. Nick Oberheiden, Founding Attorney of Oberheiden P.C.
If you or a loved one developed cancer after using Dupixent, this article provides an introduction to what you need to know in order to make an informed decision about whether to pursue compensation. With that said, every case is unique, and anyone who has questions about their legal rights should schedule a free case review with an experienced Dupixent attorney.
When to File a Dupixent Lawsuit: What Patients and Family Members Need to Know
Here are 10 key facts for patients (and family members of patients) who took Dupixent and later developed CTCL:
1. The Drug Manufacturers Behind Dupixent Are Facing Multiple Lawsuits
Dupixent, which is prescribed to treat eczema (atopic dermatitis), asthma, chronic obstructive pulmonary disease (COPD), chronic sinusitis, nasal polyps, and eosinophilic esophagitis, is currently at the center of several lawsuits pending against Sanofi and Regeneron. Patients treated with Dupixent and family members are alleging that these companies failed to warn that using Dupixent could lead to a CTCL diagnosis in some cases.
2. Dupixent Lawsuits Involve Claims Related to Cutaneous T-Cell Lymphoma (CTCL)
The Dupixent lawsuits filed to date involve claims related to cutaneous T-cell lymphoma (CTCL), a type of skin cancer that affects the white blood cells. Plaintiffs allege that their (or their loved one’s) cancer diagnoses are the result of using this allegedly dangerous drug. They also allege that Sanofi and Regeneron either knew or should have known that receiving Dupixent injections would put patients at significantly higher risk for developing undiagnosed lymphoma.
3. A Retrospective Cohort Study Linked Dupixent Use to CTCL Last Year
Dupixent is widely prescribed for asthma and the other conditions listed above—and it has been for several years. The current wave of Dupixent lawsuits is the result of a retrospective cohort study published in 2024. That study concluded that:
“An increased risk of CTCL was found in the cohort of . . . patients who used dupilumab (odds ratio 4.1003, 95% confidence interval 2.055-8.192). . . . [and m]ost (27/41) cases of CTCL were diagnosed more than 1 year after dupilumab use.”
Dupilumab is the generic name for Dupixent. If the study’s findings are accurate, this means that Dupixent patients may have clear grounds to pursue claims against Sanofi and Regeneron. If Dupixent users are at increased risk of developing CTCL compared to non-Dupixent users, this could mean that these companies’ failure to disclose the increased risk of CTCL on the drug’s label constitutes a violation of their patient safety obligations.
4. Dupixent-Linked CTCL Could Entitle Patients and Families to Financial Compensation
If Sanofi and Regeneron had a duty to warn patients about the risk of developing cutaneous T-cell lymphoma (CTCL) as a result of taking Dupixent and failed to do so, this could entitle patients and families to financial compensation. As noted above, multiple cases are already making their way through the legal process. As discussed in greater detail below, patients and family members who have grounds to take legal action can seek financial compensation for various types of immediate and long-term financial and non-financial losses.
5. Patients Can Seek Compensation for Their CTCL Symptoms, Medical Bills, and Other Losses
Patients harmed by Dupixent have the right to seek compensation for all of the financial and non-financial consequences of their cutaneous T-cell lymphoma (CTCL) diagnoses. By filing a Dupixent lawsuit, eligible patients who used Dupixent to treat conditions such as eczema and asthma can seek compensation for the present and future costs of their symptoms, including:
- Medical expenses (including dermatologic therapy)
- Medications, medical supplies, and other out-of-pocket costs
- Lost wages or salary, lost benefits, and lost future earnings
- Physical pain and suffering, emotional trauma, and permanent scarring
- Loss of companionship, loss of consortium, and loss of enjoyment of life
Even though many patients still have plenty of time to file a Dupixent lawsuit, it is best to discuss your legal options with a lawyer promptly. If you have grounds to take legal action related to your CTCL development, filing promptly will help protect your legal rights and maximize your chances of recovery.
6. Families Can Seek Compensation for Loved Ones’ Premature Deaths Resulting from CTCL
Family members who have tragically lost a loved one following a CTCL diagnosis may be eligible to file a Dupixent wrongful death lawsuit against Sanofi and Regeneron. In wrongful death cases involving CTCL diagnoses linked to Dupixent, eligible family members can seek compensation for their financial and non-financial losses resulting from their loved one’s untimely death.
Some reports have suggested that the effects of Dupixent could mask early signs of cutaneous T-cell lymphoma (CTCL). If this is true, it could make diagnosing Dupixent-linked CTCL more difficult—and this delayed diagnosis, in turn, could increase patients’ risk of death. These reports are still under investigation, and they have the potential to play a key role in the Dupixent litigation going forward.
7. Filing a Dupixent Lawsuit Requires Medical Evidence (i.e. Medical Records)
In all cases, filing a Dupixent lawsuit requires medical evidence of both the patient’s Dupixent use and the patient’s cancer diagnosis. Patients and family members who have questions about filing a lawsuit should gather medical records from their (or their loved one’s) healthcare providers if possible. But, patients and their family members can also rely on their lawyers to gather the required medical documentation if necessary.
Documentation of a patient’s treatment (and treatment-related expenses) for cutaneous T-cell lymphoma (CTCL) will be necessary as well. Here too, potential plaintiffs should collect these records if they can, but having these records in your possession is not a prerequisite for talking to a lawyer.
8. Filing a Dupixent Lawsuit Requires Documentation of Patients’ (or Family Members’) Financial and Non-Financial Losses
Along with medical documentation, filing a Dupixent lawsuit also requires documentation of patients’ (or family members’) financial and non-financial losses. This means that potential plaintiffs should try to gather their (or their loved one’s) employment records, receipts, and any other potentially relevant documentation as well. Here too, a Dupixent lawyer will be able to help—and there are additional forms of documentation that plaintiffs’ lawyers will need to generate during the legal process.
9. There is Not (and Probably Won’t Be) a Dupixent Class Action Lawsuit
Many people have questions about whether there is a Dupixent class action lawsuit. There is not a class action lawsuit presently—and there probably won’t be one in the future.
Why? Because this type of lawsuit is not well-suited to class action litigation. Class action lawsuits involve similar claims filed by similarly situated plaintiffs, and the value of each plaintiff’s claim is usually relatively low. However, cancer affects everyone differently, and the financial and non-financial costs associated with a CTCL diagnosis can be substantial. As a result, we anticipate that Dupixent attorneys will continue to file their clients’ lawsuits individually; and, if enough lawsuits get filed, we may see them get consolidated into a national multidistrict litigation (MDL) proceeding.
10. You Can Hire a Dupixent Lawyer at No Out-of-Pocket Cost
If you have questions about filing a Dupixent lawsuit, talking to a lawyer is the first major step toward making an informed decision. As we just discussed, every case is unique, and patients and family members need legal advice that is custom-tailored to their specific circumstances.
You should be able to schedule a free case review with a Dupixent lawyer; and, if you have grounds to take legal action, you should be able to hire a lawyer to represent you at no out-of-pocket cost. This is known as contingency-fee representation. If your lawsuit is successful (i.e., if you receive a settlement or verdict), your legal fees will be deducted from your financial recovery. If your lawsuit is unsuccessful, you will owe nothing.
